Parathyroid hormone

(Natpara®)

Parathyroid hormone

Drug updated on 9/4/2024

Dosage FormInjection (subcutaneous; 25 mcg, 50 mcg, 75 mcg, 100 mcg)
Drug ClassParathyroid hormones
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Natpara (parathyroid hormone) is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.
  • This summary is based on the review of five systematic review(s)/meta-analysis(es). [1-5]
  • Patients with Chronic Hypoparathyroidism Refractory to Standard Therapy: Continuous subcutaneous PTH infusion resulted in rapid clinical and biochemical improvement without severe adverse events.
  • Comparative Effectiveness of PTH Replacement vs. Standard Therapy: PTH replacement therapy showed no significant difference in serum calcium levels compared to standard calcium and vitamin D therapy, with a trend towards lower 24-hour urinary calcium in the PTH group, though this was not statistically significant.
  • Management of Postoperative Hypoparathyroidism: Different early postoperative hypoparathyroidism treatment strategies were effective in preventing major hypocalcemia-related complications, with no significant difference in long-term hypoparathyroidism incidence among various supplementation protocols.
  • The incidence of serious adverse events was similar between PTH replacement therapy and control groups (RR 1.35; 95% CI 0.58, 3.16; P = 0.49).
  • There is no population types or subgroups information available in the reviewed studies.